MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
P/E ratio for MaxCyte, Inc. (MXCT)
P/E ratio as of 2023: -12.80
According to MaxCyte, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.80. At the end of 2022 the company had a P/E ratio of -28.07.
P/E ratio history for MaxCyte, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -12.80 |
| 2022 | -28.07 |
| 2021 | -45.88 |
| 2020 | -93.41 |
| 2019 | -70.62 |
| 2018 | -98.10 |
| 2017 | -83.39 |
| 2016 | -170.31 |
| 2015 | -511.24 |
| 2014 | -402.29 |
| 2013 | -771.24 |
| 2012 | -371.65 |